AP NEWS

Data on Exicure’s TLR9 Agonist Spherical Nucleic Acid (SNA™) Construct Presented at the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

October 1, 2018

SKOKIE, Ill.--(BUSINESS WIRE)--Oct 1, 2018--Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, presented data in a poster session on Sunday, September 30 at the 4 th CRI-CIMT-EATI-AACR International Immunotherapy Conference: Translating Science into Survival in New York, New York.

The poster titled “ AST-008, a novel TLR9 agonist SNA, induces abscopal antitumor effects in mouse tumor models” supports the ongoing clinical development of the Company’s proprietary SNA™ technology and highlights new data showing the effects of Exicure’s technology on mouse tumor models through a systemic immune response.

These data presented in the poster session show that both subcutaneous and intra-tumoral administration of AST-008 into one tumor lesion in the mouse model leads to systemic antitumor activity at a distant, un-injected tumor.

“These new data, along with data from other pre-clinical tumor model studies in combination with an anti-PD-1 antibody, and our recently completed Phase 1 trial support the continued advancement of Exicure’s drug candidate AST-008,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “We intend to launch our Phase 1b/2 clinical trial in combination with a checkpoint inhibitor in Q4 of 2018.”

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure’s proprietary 3-dimensional, spherical nucleic acid spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL. www.exicuretx.com

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical programs do not advance into the clinic or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of pre-clinical and clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Exicure’s pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005207/en/

CONTACT: MacDougall Biomedical Communications

Karen Sharma, 781-235-3060

ksharma@macbiocom.com

or

The Del Mar Consulting Group, Inc.

Robert Prag, 858-794-9500

President

bprag@delmarconsulting.com

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY PHARMACEUTICAL

SOURCE: Exicure, Inc.

Copyright Business Wire 2018.

PUB: 10/01/2018 07:00 AM/DISC: 10/01/2018 07:01 AM

http://www.businesswire.com/news/home/20181001005207/en

AP RADIO
Update hourly